Taro Pharmaceutical Industries Ltd (TARO)
42.41
-0.07
(-0.16%)
USD |
NYSE |
Apr 26, 16:00
42.41
0.00 (0.00%)
After-Hours: 20:00
Taro Pharmaceutical Industries Research and Development Expense (Quarterly): 13.59M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 13.59M |
| September 30, 2023 | 14.32M |
| June 30, 2023 | 16.14M |
| March 31, 2023 | 16.31M |
| December 31, 2022 | 12.91M |
| September 30, 2022 | 11.52M |
| June 30, 2022 | 11.51M |
| March 31, 2022 | 14.89M |
| December 31, 2021 | 14.20M |
| September 30, 2021 | 12.50M |
| June 30, 2021 | 12.95M |
| March 31, 2021 | 16.59M |
| December 31, 2020 | 14.08M |
| September 30, 2020 | 16.55M |
| June 30, 2020 | 12.93M |
| March 31, 2020 | 15.80M |
| December 31, 2019 | 15.00M |
| September 30, 2019 | 15.54M |
| June 30, 2019 | 13.44M |
| March 31, 2019 | 20.51M |
| December 31, 2018 | 14.73M |
| September 30, 2018 | 14.66M |
| June 30, 2018 | 13.34M |
| March 31, 2018 | 20.31M |
| December 31, 2017 | 17.46M |
| Date | Value |
|---|---|
| September 30, 2017 | 18.00M |
| June 30, 2017 | 14.66M |
| March 31, 2017 | 19.88M |
| December 31, 2016 | 18.00M |
| September 30, 2016 | 14.84M |
| June 30, 2016 | 17.92M |
| March 31, 2016 | 19.95M |
| December 31, 2015 | 17.94M |
| September 30, 2015 | 18.73M |
| June 30, 2015 | 14.54M |
| March 31, 2015 | 23.86M |
| December 31, 2014 | 12.83M |
| September 30, 2014 | 13.83M |
| June 30, 2014 | 14.99M |
| March 31, 2014 | 13.17M |
| December 31, 2013 | 15.12M |
| September 30, 2013 | 14.93M |
| June 30, 2013 | 12.21M |
| March 31, 2013 | 12.20M |
| December 31, 2012 | 11.84M |
| September 30, 2012 | 10.94M |
| June 30, 2012 | 11.52M |
| March 31, 2012 | 9.847M |
| December 31, 2011 | 8.867M |
| September 30, 2011 | 6.934M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
11.51M
Minimum
Jun 2022
16.59M
Maximum
Mar 2021
14.25M
Average
14.20M
Median
Dec 2021
Research and Development Expense (Quarterly) Benchmarks
| InspireMD Inc | 2.035M |
| Ayala Pharmaceuticals Inc | 5.41M |
| BiomX Inc | 2.675M |
| Alpha Tau Medical Ltd | 7.49M |
| Pluri Inc | 2.964M |